IP Library › Granted Patent US 7,531,628
Granted Patent B2
US 7,531,628 · App. 11/138,949 · Granted May 12, 2009

Canine CD20 compositions

Assignee: IDEXX Laboratories, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,531,628
App. No.
11/138,949
Granted
May 12, 2009
Kind
B2
Abstract

The invention provides canine CD20 nucleotide and protein sequences. These compositions are useful in the diagnosis and treatment of, e.g., CD20+ B-cell lymphoma, immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, and systemic lupus erythematosus (SLE) in canines and felines.

Claims (5)

1. An isolated canine CD20 protein comprising the amino acid sequence shown in SEQ ID NO: 6.

2. The isolated protein of claim 1 , wherein the protein is present in a fusion protein.

3. An isolated polypeptide comprising the amino acid sequence shown in SEQ ID NO: 10.

4. The isolated polypeptide of claim 3 , wherein the polypeptide is present in a fusion protein.

5. An isolated polypeptide, wherein the polypeptide comprises the amino acid sequence shown in SEQ ID NO: 11.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2005
From: BEALL, MELISSA L.
To: IDEXX LABORATORIES, INC.
Reel/Frame 016422/0087 →
Continuity (2)
Provisional Application 6057517200 · May 28, 2004
Related Publication 20050271662A1 · Dec 8, 2005